Endocyte Receives Buy Rating from Chardan Capital (ECYT)
A number of other analysts have also recently weighed in on ECYT. Analysts at Brean Capital initiated coverage on shares of Endocyte in a research note on Tuesday, July 8th. They set a “buy” rating and a $22.00 price target on the stock. Separately, analysts at Zacks upgraded shares of Endocyte from a “neutral” rating to an “outperform” rating in a research note on Monday, July 7th. They now have a $7.90 price target on the stock. Finally, analysts at RBC Capital cut their price target on shares of Endocyte from $20.00 to $15.00 in a research note on Wednesday, June 18th. They now have an “outperform” rating on the stock. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $24.34.
Endocyte (NASDAQ:ECYT) traded up 16.01% on Wednesday, hitting $7.10. The stock had a trading volume of 4,179,786 shares. Endocyte has a 52-week low of $5.91 and a 52-week high of $33.70. The stock has a 50-day moving average of $6.50 and a 200-day moving average of $11.97. The company’s market cap is $294.7 million.
Endocyte (NASDAQ:ECYT) last released its earnings data on Tuesday, July 29th. The company reported $0.52 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.10 by $0.42. The company had revenue of $49.17 million for the quarter, compared to the consensus estimate of $26.62 million. Endocyte’s revenue was up 198.4% compared to the same quarter last year. On average, analysts predict that Endocyte will post $-0.18 earnings per share for the current fiscal year.
Endocyte, Inc (NASDAQ:ECYT) is a biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.